Strategic Counsel Rooted in Rigorous Analytics
From early-stage candidates to brand leaders in biopharmaceutical and medical technology, we work across every phase of your products’ lifecycle to maximize your commercial, R&D, corporate and business development opportunities.
Our formula for success:
- Start with a deep dive into the data
- Apply robust qualitative and quantitative analytics
- Leverage vast scientific, clinical, commercial, and transactional expertise
- Senior leadership involvement from project concept through delivery
The result: Clarity out of ambiguity — driving actionable growth strategies.
Investment Banking Powered by Research-Driven Insight
The Back Bay Life Science Advisors approach:
Back Bay combines insights generated from in-depth scientific, clinical, and commercial analysis with exceptional transaction execution capabilities to provide our clients with tailored, sound advice on realizing value.
Our offerings include:
- Mergers, acquisitions and divestitures
- Cross-border transactions
- Structured transactions involving complex options
- Financing support
- Valuation and fairness opinions
The result: Seamless integration from asset valuation and positioning through to successful deal execution—a formula for maximizing value in a smooth, efficient process.
Back Bay Life Science Advisors analyzed the United States biosimilars market for our latest white paper, US Biosimilars: Opportunities and Challenges.
For nearly a decade, biosimilars have loomed large over every facet of the US healthcare debate. Depending on where you sit, biosimilars represent either a dreaded threat to innovation or a hoped-for answer to sky-high drug prices. However, neither scenario has fully come to pass, and although we still expect biosimilars to effect change in the biologics market, when it will happen and to what degree are still unknown. In this white paper, we outline trends and potential scenarios for US biosimilars based on current European and US market dynamics. We examine the biosimilar landscape and conclude with thoughts on how developers of biologics can best adapt to an evolving market.
William T. Andrews MD FACP
Former, Senior VP, Business Development
“I have worked with Back Bay on a number of assignments and find it unique and very valuable to be able to work with the same advisors from the development of the business strategy though to the transaction process . The continuity throughout the process has been essential for an effective process and of course a successful transaction.”
Chief Executive Officer
“The BB team really helped us answer some difficult questions. Great insights intelligently delivered.”
Chief Operating Officer
“Back Bay has helped us, quickly, efficiently, and with great expertise, to explore new solutions and opportunities as well as execute in critical transactional circumstances. The Back Bay Team has been great to work with.”